ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Updated Corporate Overview

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jul 16, 2021 1:24pm

85 Views

Post# 33560239

RE:Updated Corporate Overview

Past time to dump Goldstein's mantra of best in class not first in class.

Aducanumab is in the books now and its sole accomplshment was to reinforce the growing public mistrust of regulators, is that really the class we want to be best of? Dump the mantra and those that pushed it, Promis would be ahead of the game now if it had called out Aducanumab for the scat sample that is, instead trying to buff a shine onto it.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing